Ian Smith

Ian Smith is a biotechnology leader with more than 25 years of strategic leadership, corporate and business development, finance and operations experience. He serves as a Senior Advisor to Bain Capital Life Sciences, Executive Chair of Solid Biosciences (Nasdaq: SLDB, gene therapy for Duchenne Muscular Dystrophy), a member of the Board of Directors of Foghorn Therapeutics (Nasdaq: FHTX), a member of the Board of Alkeus Pharmaceuticals and, formerly Executive Chair of Viacyte Inc. (Cell therapy for Type 1 Diabetes, acquired by Vertex Pharmaceuticals). He also provides executive advisory services to multiple Biotech companies. Prior to this, Ian was Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals Inc., as well as Chief Financial Officer between 2001 and 2019.